Compare Ascendis Pharma A/S (ASND) vs iShares Bitcoin Trust (IBIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs iShares Bitcoin Trust — how do they compare? Ascendis Pharma A/S trades at $270.45 (market cap $17.74B), while iShares Bitcoin Trust trades at $35.43. The key difference: Ascendis Pharma A/S is trading nearer its 52-week high, iShares Bitcoin Trust nearer its low. Which is the better fit depends on your goals.
| ASND | IBIT | |
|---|---|---|
Market Cap | $17.74B | — |
Sector | Health | Crypto-linked |
52-Week High | $277.18 | $71.29 |
52-Week Low | $163.32 | $33.29 |
Enterprise Value | $18.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
IBIT trades at $36.23, up 1.17% today, with neutral technical signals from moving averages and oscillators. Support and resistance cluster around $35-$36. The stock's financial ratios are unavailable, but recent news highlights its position as a leading spot Bitcoin ETF with $44.9 billion in assets under management as of June 2026, per The Motley Fool.
Outlook remains tied to Bitcoin ETF flows and investor sentiment toward crypto-linked equities. Risks include market volatility and competitive pressure from other ETFs. Institutional interest is strong, but performance depends heavily on broader cryptocurrency trends and regulatory developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About iShares Bitcoin Trust
IBIT is a spot Bitcoin ETF that tracks the price of Bitcoin directly. Managed by BlackRock, it offers investors a regulated way to gain exposure to the digital asset within a traditional brokerage account.
Read more on IBIT →
